FATTIZZO, BRUNO
FATTIZZO, BRUNO
Dipartimento di Oncologia ed Emato-Oncologia
Natural history of chronic idiopathic neutropenia of the adult
2024 B. Fattizzo, A. Bosi, M. Sorrenti, D. Murgia, L. Pettine, M. Bortolotti, G.A. Croci, F. Passamonti, W. Barcellini
Deciphering cytopenias in internal medicine: a single-center observational study
2024 S. Leoni, M. Ferraresi, I. Motta, C. Hu, A.L. Fracanzani, W. Barcellini, B. Fattizzo
Recombinant erythropoietin in autoimmune hemolytic anemia with inadequate bone marrow response: a prospective analysis
2024 B. Fattizzo, G.L. Pedone, C. Brambilla, L. Pettine, A. Zaninoni, F. Passamonti, W. Barcellini
Transfusions in autoimmune hemolytic anemias: Frequency and clinical significance of alloimmunization
2024 F. Versino, N. Revelli, S. Villa, L. Pettine, A. Zaninoni, D. Prati, F. Passamonti, W. Barcellini, B. Fattizzo
Diagnosis and management of Evans syndrome in adults: first consensus recommendations
2024 B. Fattizzo, M. Marchetti, M. Michel, S. Cantoni, H. Frederiksen, G. Giordano, A. Glenthøj, T.J. González-López, I. Murakhovskaya, M. Napolitano, M. Mingot, M. Arguello, A. Patriarca, S. Raso, N. Vianelli, W. Barcellini
Editorial: Practical recommendations and consensus for the management of immune mediated hematologic diseases
2024 B. Fattizzo, S. Berentsen, W. Barcellini
Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy
2024 F. Versino, B. Fattizzo
Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function
2024 J. Szer, J. Panse, A. Kulasekararaj, M. Oliver, B. Fattizzo, J. Nishimura, R. Horneff, J. Szamosi, R. Peffault de Latour
Use of steroids in the management of low-risk myelodysplastic syndromes with autoimmune features
2023 B. Fattizzo, F. Serpenti, F. Versino, G. Cassanello, L.M. Cro, M. Barbieri, G.A. Croci, N. Revelli, M.G. Della Porta, W. Barcellini
Luspatercept in combination with recombinant erythropoietin in patients with myelodysplastic syndrome with ring sideroblasts: Stimulating early and late‐stage erythropoiesis
2023 B. Fattizzo, F. Versino, M. Bortolotti, L. Rizzo, M. Riva, W. Barcellini
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "Old-fashioned" Drug be Effective?
2023 M. Riva, A. Bosi, L. Rizzo, F. Mazzon, S. Ferrari, F. Lussana, L. Borin, A. Castelli, R. Cairoli, W. Barcellini, A. Molteni, B. Fattizzo
Drug design and development for rare hematologic diseases
2023 B. Fattizzo, M. Capecchi, I. Motta
Cytokine polymorphisms in patients with autoimmune hemolytic anemia
2023 A. Zaninoni, B. Fattizzo, L. Pettine, C. Vercellati, A.P. Marcello, W. Barcellini
Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature
2023 N. Galli, L. Pettine, M. Panigada, L. Daprai, G. Suriano, A. Grancini, W. Barcellini, B. Fattizzo
The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket?
2023 S. Berentsen, B. Fattizzo, W. Barcellini
Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps
2023 F.V.M. Mulder, D. Evers, M. de Haas, M.J. Cruijsen, S.J. Bernelot Moens, W. Barcellini, B. Fattizzo, J.M.I. Vos
Rise of the planet of rare anemias: An update on emerging treatment strategies
2023 B. Fattizzo, I. Motta
Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data
2023 A. Bosi, W. Barcellini, F. Passamonti, B. Fattizzo
Aplastic anemia after SARS-CoV-2 infection or vaccines: case series and literature review
2023 B. Fattizzo, R. Pasquale, G.A. Croci, L. Pettine, G. Cassanello, W. Barcellini
Cell Population Data NE-WX, NE-FSC, LY-Y of Sysmex XN-9000 can provide additional information to differentiate macrocytic anaemia from myelodysplastic syndrome: A preliminary study
2022 D. Di Luise, J.A. Giannotta, M. Ammirabile, V. De Zordi, S. Torricelli, S. Bottalico, M.L. Chiaretto, B. Fattizzo, A.C. Migliorini, F. Ceriotti